{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007665","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.690229+00:00","generated_at":"2026-05-21T09:31:44.249940+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients","bullets":["Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.","Operating loss $4.1M (Q1 2025) vs $3.1M (Q1 2024); R&D spending up $0.9M on APR-1051 and ATRN-119 trials.","ATRN-119 ABOYA-119 trial: 3 patients at 550mg BID had tumor shrinkage of 7%, 14%, and 21% below RP2D.","APR-1051 ACESOT-1051 trial enrolling at 100mg QD; next cohort 150mg; preliminary efficacy data expected H2 2025.","Entered Material Transfer Agreement with MD Anderson to study APR-1051 in head and neck cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007665","json":"https://secwatch.observer/filing/0001558370-25-007665.json","markdown":"https://secwatch.observer/filing/0001558370-25-007665.md","text":"https://secwatch.observer/filing/0001558370-25-007665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/0001558370-25-007665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837025007665/apre-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:31:44.249940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}